NO20092637L - Fremgangsmater for behandling - Google Patents
Fremgangsmater for behandlingInfo
- Publication number
- NO20092637L NO20092637L NO20092637A NO20092637A NO20092637L NO 20092637 L NO20092637 L NO 20092637L NO 20092637 A NO20092637 A NO 20092637A NO 20092637 A NO20092637 A NO 20092637A NO 20092637 L NO20092637 L NO 20092637L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- treatment
- present
- compositions
- covered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Sammendrag Foreliggende oppfinnelse gjelder preparater og fremgangsmåter som er anvendbare for behandling av forskjellige kreftformer. Terapeutiske kombinasjoner og fremgangsmåter for anvendelse derav dekkes også i den foreliggende patentsøknad.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87458906P | 2006-12-13 | 2006-12-13 | |
US87093706P | 2006-12-20 | 2006-12-20 | |
US94601107P | 2007-06-25 | 2007-06-25 | |
US97927407P | 2007-10-11 | 2007-10-11 | |
PCT/US2007/025398 WO2008076278A2 (en) | 2006-12-13 | 2007-12-11 | Methods of cancer treatment with igf1r inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20092637L true NO20092637L (no) | 2009-09-11 |
Family
ID=39400630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20092637A NO20092637L (no) | 2006-12-13 | 2009-07-10 | Fremgangsmater for behandling |
Country Status (12)
Country | Link |
---|---|
US (1) | US20110262525A1 (no) |
EP (1) | EP2104501B1 (no) |
JP (2) | JP2010513278A (no) |
CN (1) | CN102123712B (no) |
AU (1) | AU2007334456A1 (no) |
CA (1) | CA2672828A1 (no) |
CL (2) | CL2012000519A1 (no) |
MX (1) | MX2009006466A (no) |
NO (1) | NO20092637L (no) |
NZ (1) | NZ578329A (no) |
TW (1) | TW200840583A (no) |
WO (1) | WO2008076278A2 (no) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602006021142D1 (de) | 2005-02-03 | 2011-05-19 | Gen Hospital Corp | Verfahren zur behandlung von gefitinib-resistentem krebs |
CN103110948A (zh) | 2005-11-04 | 2013-05-22 | 惠氏公司 | mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合 |
AU2012203443B2 (en) * | 2007-03-02 | 2014-03-06 | Amgen Inc. | Methods and compositions for treating tumor diseases |
WO2008108986A2 (en) * | 2007-03-02 | 2008-09-12 | Amgen Inc. | Methods and compositions for treating tumor diseases |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
EP2247757A2 (en) * | 2007-12-18 | 2010-11-10 | Schering Corporation | Biomarkers for sensitivity to anti-igf1r therapy |
TW200948380A (en) * | 2008-04-11 | 2009-12-01 | Galaxy Biotech Llc | Combination of HGF inhibitor and PTEN agonist to treat cancer |
DK2656844T3 (en) | 2008-06-17 | 2015-03-02 | Wyeth Llc | ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE |
CN105963313A (zh) | 2008-08-04 | 2016-09-28 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
AU2010232729A1 (en) | 2009-03-31 | 2011-10-20 | Arqule, Inc. | Substituted indolo-pyridinone compounds |
AU2010234968B2 (en) | 2009-04-06 | 2015-05-14 | Wyeth Llc | Treatment regimen utilizing neratinib for breast cancer |
JP2013512215A (ja) * | 2009-11-25 | 2013-04-11 | ノバルティス アーゲー | 二環式ヘテロアリールのベンゼン縮合6員酸素含有ヘテロ環誘導体 |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
US9427477B2 (en) | 2011-05-09 | 2016-08-30 | Mayo Foundation For Medical Education And Research | Cancer treatments |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
PT3176170T (pt) | 2012-06-13 | 2019-02-05 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
EP2903610B1 (en) | 2012-10-01 | 2021-11-03 | Mayo Foundation For Medical Education And Research | Cancer treatments |
EP2909802B1 (en) * | 2012-10-22 | 2020-08-12 | University of Southern California | Diet formulations promoting tissue/organ regeneration |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
PE20152033A1 (es) | 2013-04-19 | 2016-01-21 | Incyte Holdings Corp | Heterociclos bicicliclos como inhibidores de fgfr |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
RU2715893C2 (ru) * | 2014-03-26 | 2020-03-04 | Астекс Терапьютикс Лтд | Комбинации ингибитора fgfr и ингибитора igf1r |
HUE053654T2 (hu) | 2014-03-26 | 2021-07-28 | Astex Therapeutics Ltd | FGFR- és CMET-inhibitorok kombinációi a rák kezelésére |
JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
CN113134095A (zh) * | 2014-06-16 | 2021-07-20 | 梅约医学教育与研究基金会 | 治疗骨髓瘤 |
US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
CN106999517A (zh) * | 2014-10-07 | 2017-08-01 | 免疫医疗公司 | 抗体‑药物缀合物的新辅助剂用途 |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
CN104478890B (zh) * | 2014-11-26 | 2016-09-14 | 浙江大学 | 一种全反式维甲酸-喜树碱类抗癌药物偶联物及其制备方法和应用 |
CN104447777B (zh) * | 2014-11-26 | 2016-09-14 | 浙江大学 | 一种辣椒碱-喜树碱类抗癌药物偶联物及其制备方法和应用 |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
EP3617205B1 (en) | 2015-02-20 | 2021-08-04 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體-抗體組合物及其製造及使用方法 |
EP3353164B1 (en) | 2015-09-23 | 2021-11-03 | Janssen Pharmaceutica, N.V. | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
SI3353177T1 (sl) | 2015-09-23 | 2020-08-31 | Janssen Pharmaceutica Nv | Triciklični heterocikli za zdravljenje raka |
CN109069622A (zh) * | 2015-09-30 | 2018-12-21 | 詹森生物科技公司 | 特异性结合人cd40的拮抗性抗体和使用方法 |
TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
US11571469B2 (en) | 2016-01-07 | 2023-02-07 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression |
US11351254B2 (en) | 2016-02-12 | 2022-06-07 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
WO2017165440A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
CA3018340A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
US10105389B1 (en) | 2016-04-01 | 2018-10-23 | Howard Alliger | Method and compositions for treating cancerous tumors |
US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
CN107569493B (zh) * | 2016-07-04 | 2020-03-06 | 北京市神经外科研究所 | 氟维司群在制备治疗无功能垂体腺瘤的药物中的用途 |
EP4177271A1 (en) | 2016-09-01 | 2023-05-10 | Mayo Foundation for Medical Education and Research | Carrier-pd-l1 binding agent compositions for treating cancers |
US11160876B2 (en) | 2016-09-01 | 2021-11-02 | Mayo Foundation For Medical Education And Research | Methods and compositions for targeting t-cell cancers |
CA3035653A1 (en) | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
EP3510048A1 (en) | 2016-09-06 | 2019-07-17 | Mayo Foundation for Medical Education and Research | Methods of treating pd-l1 expressing cancer |
EP3509635A1 (en) | 2016-09-06 | 2019-07-17 | Vavotar Life Sciences LLC | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
CA3059593A1 (en) * | 2017-05-21 | 2018-11-29 | Igf Oncology, Llc | An insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
CA3099116A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Salts of an fgfr inhibitor |
CN112867716A (zh) | 2018-05-04 | 2021-05-28 | 因赛特公司 | Fgfr抑制剂的固体形式和其制备方法 |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
JOP20220083A1 (ar) | 2019-10-14 | 2023-01-30 | Incyte Corp | حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
CN113512116B (zh) * | 2020-04-10 | 2022-09-20 | 苏州普乐康医药科技有限公司 | 一种抗igf-1r抗体及其应用 |
CN112125916A (zh) * | 2020-09-28 | 2020-12-25 | 杭州仁者生物科技有限公司 | 胰岛素样生长因子-1受体的新型小分子抑制剂及其用途 |
US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US6300129B1 (en) * | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
AR032028A1 (es) | 2001-01-05 | 2003-10-22 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
AR035885A1 (es) * | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
FR2834991B1 (fr) | 2002-01-18 | 2004-12-31 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
FR2834990A1 (fr) | 2002-01-18 | 2003-07-25 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
FR2834900B1 (fr) | 2002-01-18 | 2005-07-01 | Pf Medicament | Nouvelles compositions a activite anti-igf-ir et anti-egfr et leurs applications |
JP4606739B2 (ja) * | 2002-01-18 | 2011-01-05 | ピエール、ファーブル、メディカマン | 新規抗igf−ir抗体およびその使用 |
EP1496982A4 (en) | 2002-04-16 | 2006-07-19 | Merck & Co Inc | SOLID FORMS OF SALTS WITH TYROSINE KINASE EFFECT |
WO2003100008A2 (en) * | 2002-05-24 | 2003-12-04 | Schering Corporation | Neutralizing human anti-igfr antibody |
US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
NZ540971A (en) | 2003-02-13 | 2008-04-30 | Pfizer Prod Inc | Uses of anti-insulin-like growth factor I receptor antibodies |
EP1603948A1 (en) | 2003-03-14 | 2005-12-14 | Pharmacia Corporation | Antibodies to igf-i receptor for the treatment of cancers |
JP4473257B2 (ja) | 2003-04-02 | 2010-06-02 | エフ.ホフマン−ラ ロシュ アーゲー | インスリン様成長因子i受容体に対する抗体及びその使用 |
WO2005016970A2 (en) | 2003-05-01 | 2005-02-24 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
WO2005082415A2 (en) * | 2004-02-25 | 2005-09-09 | Dana Farber Cancer Institute, Inc. | Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth |
WO2006060419A2 (en) * | 2004-12-03 | 2006-06-08 | Schering Corporation | Biomarkers for pre-selection of patients for anti-igf1r therapy |
CA2604393A1 (en) * | 2005-04-15 | 2006-10-26 | Schering Corporation | Methods and compositions for treating or preventing cancer |
-
2007
- 2007-12-11 MX MX2009006466A patent/MX2009006466A/es not_active Application Discontinuation
- 2007-12-11 US US12/518,409 patent/US20110262525A1/en not_active Abandoned
- 2007-12-11 CA CA002672828A patent/CA2672828A1/en not_active Abandoned
- 2007-12-11 NZ NZ578329A patent/NZ578329A/en not_active IP Right Cessation
- 2007-12-11 JP JP2009541358A patent/JP2010513278A/ja not_active Withdrawn
- 2007-12-11 CN CN200780051289.8A patent/CN102123712B/zh not_active Expired - Fee Related
- 2007-12-11 WO PCT/US2007/025398 patent/WO2008076278A2/en active Application Filing
- 2007-12-11 EP EP07862806.2A patent/EP2104501B1/en active Active
- 2007-12-11 AU AU2007334456A patent/AU2007334456A1/en not_active Abandoned
- 2007-12-12 TW TW096147348A patent/TW200840583A/zh unknown
-
2009
- 2009-07-10 NO NO20092637A patent/NO20092637L/no not_active Application Discontinuation
-
2012
- 2012-02-28 CL CL2012000519A patent/CL2012000519A1/es unknown
- 2012-02-28 CL CL2012000518A patent/CL2012000518A1/es unknown
- 2012-07-12 JP JP2012156460A patent/JP2012193204A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2007334456A1 (en) | 2008-06-26 |
JP2012193204A (ja) | 2012-10-11 |
CL2012000518A1 (es) | 2012-10-05 |
WO2008076278A3 (en) | 2009-05-07 |
MX2009006466A (es) | 2009-06-26 |
CN102123712A (zh) | 2011-07-13 |
WO2008076278A8 (en) | 2013-03-28 |
WO2008076278A4 (en) | 2009-06-25 |
CA2672828A1 (en) | 2008-06-26 |
US20110262525A1 (en) | 2011-10-27 |
JP2010513278A (ja) | 2010-04-30 |
EP2104501A2 (en) | 2009-09-30 |
WO2008076278A2 (en) | 2008-06-26 |
EP2104501B1 (en) | 2014-03-12 |
CL2012000519A1 (es) | 2012-10-05 |
NZ578329A (en) | 2012-05-25 |
CN102123712B (zh) | 2014-03-19 |
TW200840583A (en) | 2008-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20092637L (no) | Fremgangsmater for behandling | |
EA200700175A1 (ru) | Композиции и способы лечения воспалительных заболеваний | |
MX2009006704A (es) | Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa. | |
PH12014500053A1 (en) | Proteasome inhibitors | |
MX2007016322A (es) | Composiciones y metodos para el diagnostico y tratamiento de tumor. | |
EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
EA200870185A1 (ru) | Комбинации ингибиторов ang2 и vegf | |
NO20074446L (no) | DR5-antistoffer og anvendelser derav | |
ZA200702322B (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EA201170521A1 (ru) | Новые соединения | |
NO20090157L (no) | Tienpyrimidiner anvendelige som modulatorer av ionekanaler | |
MX2007011545A (es) | Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr. | |
NO20083501L (no) | Azaindoler som er anvendelige som inhibitorer for Janus-kinaser | |
CY1112889T1 (el) | Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης | |
MX2009006706A (es) | Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos. | |
NO20083011L (no) | Modulatorer av muskarine receptorer | |
IL189972A0 (en) | Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment | |
NO20064852L (no) | Azaindoler som er nyttige som inhibitorer av jak og andre proteinkinaser | |
NO20064976L (no) | Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser | |
NO20082594L (no) | Pyrimidinylbenzotiofenforbindelser | |
MY160041A (en) | Compositions and methods for treating parasitic infections | |
MA32544B1 (fr) | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique | |
EA201070327A1 (ru) | Катехоламиновые производные и их пролекарства | |
TW200630090A (en) | Triazoles useful as inhibitors of protein kinases | |
MX2010000098A (es) | Derivados de guanina policiclicos y sus metodos de uso. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: MERCK SHARP AND DOHME CORP, US Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |